---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-415545"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-10-06T20:05:32+00:00"
generated_at: "2026-10-12T16:21:57.644972+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio receives Nasdaq delisting determination; requests hearing to remain listed

## Summary
- Nasdaq Staff determined on Sept 30, 2026 to delist Kyntra Bio (KYNB) after it missed the Sept 29, 2026 deadline to comply with Listing Rule 5450(b).
- Kyntra requested a Nasdaq Hearings Panel review, which stays suspension and Form 25-NSE filing; KYNB continues trading on Nasdaq Global Select Market.
- Company previously got Nasdaq notice on April 2, 2026 for failing Rule 5450(b)(3)(A), which requires at least $50 million in total assets and total revenue.
- An extension period could run up to 180 days from the Staff delisting Determination under Listing Rule 5815(c)(1)(A), but no assurance of relief is given.
- Kyntra Bio is preparing a compliance plan for the Panel; General Counsel John Alden signed on October 6, 2026.

## SEC filing metadata
- accession: 0001193125-26-415545
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-10-06T20:05:32+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/0001193125-26-415545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/kynb-20260930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-415545
- JSON: https://secwatch.observer/filing/0001193125-26-415545.json
- Plain text: https://secwatch.observer/filing/0001193125-26-415545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.